120 related articles for article (PubMed ID: 36014378)
1. Antitumour Effects of Selected Pyridinium Salts on Sensitive Leukaemia HL60 Cells and Their Multidrug Resistant Topoisomerase II-Defective HL60/MX2 Counterparts.
Tarasiuk J; Kostrzewa-Nowak D; Żwierełło W
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014378
[TBL] [Abstract][Full Text] [Related]
2. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J
J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942
[TBL] [Abstract][Full Text] [Related]
3. Antitumour effects of selected plant polyphenols, gallic acid and ellagic acid, on sensitive and multidrug-resistant leukaemia HL60 cells.
Maruszewska A; Tarasiuk J
Phytother Res; 2019 Apr; 33(4):1208-1221. PubMed ID: 30838722
[TBL] [Abstract][Full Text] [Related]
4. Quercetin Triggers Induction of Apoptotic and Lysosomal Death of Sensitive and Multidrug Resistant Leukaemia HL60 Cells.
Maruszewska A; Tarasiuk J
Nutr Cancer; 2021; 73(3):484-501. PubMed ID: 32329631
[TBL] [Abstract][Full Text] [Related]
5. Retaining cytotoxic activity of anthrapyridone CO1 against multidrug resistant cells is related to the ability to induce concomitantly apoptosis and lysosomal death of leukaemia HL60/VINC and HL60/DOX cells.
Nowak R; Tarasiuk J
J Pharm Pharmacol; 2013 Jun; 65(6):855-67. PubMed ID: 23647679
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells.
Kostrzewa-Nowak D; Tarasiuk J
Anticancer Res; 2021 Mar; 41(3):1429-1438. PubMed ID: 33788734
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
8. Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells.
Nowak R; Tarasiuk J
Anticancer Drugs; 2012 Apr; 23(4):380-92. PubMed ID: 22198116
[TBL] [Abstract][Full Text] [Related]
9. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Tarasiuk J
Eur J Pharmacol; 2013 Dec; 721(1-3):141-50. PubMed ID: 24076328
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Hermanson DL; Das SG; Li Y; Xing C
Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
[TBL] [Abstract][Full Text] [Related]
11. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.
Xue X; Qu XJ; Gao ZH; Sun CC; Liu HP; Zhao CR; Cheng YN; Lou HX
Invest New Drugs; 2012 Feb; 30(1):212-22. PubMed ID: 20924640
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.
Lansiaux A; Laine W; Baldeyrou B; Mahieu C; Wattez N; Vezin H; Martinez FJ; Piñeyro A; Bailly C
Chem Res Toxicol; 2001 Jan; 14(1):16-24. PubMed ID: 11170504
[TBL] [Abstract][Full Text] [Related]
13. Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Anticancer Drugs; 2012 Apr; 23(4):393-405. PubMed ID: 22205152
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells.
Kik K; Wasowska-Lukawska M; Oszczapowicz I; Szmigiero L
Anticancer Res; 2009 Apr; 29(4):1429-33. PubMed ID: 19414398
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone in combination with a DNA-PK inhibitor: possible therapy of promyelocytic leukaemia resistant forms.
Mikusová V; Tichý A; Rezáčová M; Vávrová J
Folia Biol (Praha); 2011; 57(5):200-5. PubMed ID: 22123462
[TBL] [Abstract][Full Text] [Related]
16. The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.
Kostrzewa-Nowak D; Paine MJ; Wolf CR; Tarasiuk J
Br J Cancer; 2005 Jul; 93(1):89-97. PubMed ID: 15942634
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
Harker WG; Slade DL; Drake FH; Parr RL
Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
[TBL] [Abstract][Full Text] [Related]
18. The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Eur J Pharmacol; 2012 Jan; 674(2-3):112-25. PubMed ID: 22115891
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic effects of thiazolobenzimidazole derivatives on sensitive and multidrug resistant leukaemic cells.
Grimaudo S; Raimondi MV; Capone F; Chimirri A; Poretto F; Monforte AM; Simoni D; Tolomeo M
Eur J Cancer; 2001 Jan; 37(1):122-30. PubMed ID: 11165139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
